Inclusion Criteria:

          -  A patient will be eligible for inclusion in this study if he or she meets all of the
             following criteria:

               1. 18 years of age or older

               2. Histologically or Cytologically confirmed pancreatic ductal adenocarcinoma. Mixed
                  subtypes of adenocarcinoma are acceptable as long as majority of cells are ductal
                  adenocarcinoma.

               3. Resectable, locally advanced or potentially resectable pancreatic adenocarcinoma

               4. American Joint Committee on Cancer (AJCC) Stage I-III Pancreatic carcinoma.

               5. Patient has Eastern Cooperative Oncology Group( ECOG ) Performance Status 0 to 1

               6. Serum albumin ≥2.0 g/dL.

               7. Adequate hematologic function as defined by:

                    1. Absolute neutrophil count (ANC) ≥1500/mm3;

                    2. Platelets ≥70,000 x 10^3/µl;

                    3. Hemoglobin ≥9 g/dL (in the absence of red blood transfusion).

               8. Adequate liver function, as defined by:

                    1. Serum total bilirubin ≤2 x ULN mg/dL, prior to initiation of treatment.

                    2. ALT (SGPT) and AST (SGOT) ≤2.5 x upper limit of normal (ULN).

               9. Adequate renal function, as defined by serum creatinine≤ 1.5 x ULN, or creatinine
                  clearance ≥50 mL/min

              10. Women of child bearing potential and men must agree to use contraception
                  throughout the study and for one month after the last anakinra administration.

              11. Subjects must understand and sign the informed consent form

              12. Patients must be accessible for treatment and follow-up.

        Exclusion Criteria:

          -  A patient will be ineligible for inclusion in this study if he or she meets any of the
             following criteria:

               1. <18 years of age

               2. History of organ transplant.

               3. Patients with islet cell neoplasms

               4. Patients with stage IV pancreatic carcinoma

               5. Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic
                  therapy

               6. Known active infection with hepatitis B or hepatitis C

               7. Presence of clinically significant cirrhosis as determined by the investigator

               8. Known HIV positive status.

               9. Current, active immunosuppressive therapy such as cyclosporine, tacrolimus, etc.

              10. Major surgery or vascular device placement within 2 weeks prior to Day 1 of
                  treatment in study

              11. Prior chemotherapy or radiation for pancreatic cancer

              12. History of allergy or hypersensitivity to the study drugs

              13. Patient is enrolled in any outside therapeutic clinical protocol or
                  investigational trial with an investigational drug within 5 half-lives prior to
                  Study ID assignment

              14. Previous or current treatment with anakinra, canakinumab or any other IL-1
                  inhibitor

              15. Other malignancy within five years(except cutaneous, non-melanoma malignancies or
                  cervical carcinoma in site), unless the probability of recurrence of the prior
                  malignancy is <5% as determined by the Principal Investigator based on available
                  information.

              16. Significant cardiac disease (uncontrolled congestive heart failure (CHF),
                  myocardial infarction or significant ventricular arrhythmias) within the last six
                  months.

              17. Other severe and/or uncontrolled medical conditions (e.g: prior gastrointestinal
                  (GI) disease or history of prior pelvic or abdominal radiation) or other
                  conditions deemed by investigator as unsuitable for participation/enrollment

              18. Peripheral sensory neuropathy > or equal to grade 2 at baseline

              19. Abnormal liver function tests as follows:

                    1. Total bilirubin of > 2 x ULN

                    2. AST or ALT > 5x ULN

              20. Serum albumin ˂ 2.0 g/dL.

              21. Abnormal hematologic function as follows :

                    1. Absolute neutrophil count (ANC) ˂ 1500/mm3;

                    2. Platelets ˂ 70,000 x 10^3/µl;

                    3. Hemoglobin ˂ 9 g/dL (in the absence of red blood transfusion).

              22. Pregnant or nursing women

              23. No signed Informed consent form